Adenocarcinoma, Cancer of Lung, Cancer of the Lung, Carcinoma, Non-small-cell Lung, Lung Cancer, Lung Neoplasms, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms, Squamous Cell Carcinoma
Conditions
Keywords
Chemotherapy
Brief summary
The purpose of this study is to explore the detection of circulating tumor DNA, soluble immune markers, and the evaluation of peripheral blood mononuclear cells (PBMC).
Detailed description
Our plan is to collect blood from patients with advanced stage lung cancer who are scheduled to undergo systemic therapy. In this study we will utilize a novel technology for circulating tumor DNA detection in order to evaluate their presence in patients with lung cancer by comparing blood samples at six time points. We will obtain baseline blood and then collect blood at five time points during the course of the patient's chemotherapy treatments and at the end of treatment. These same blood collections will be used for the detection of soluble immune markers and evaluation of PBMCs.
Interventions
None listed
Sponsors
Mayo Clinic
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Advanced (non-resectable) malignancy in the thorax * Age \>18 years old * Willing and able to provide consent * No prior history of neoadjuvant therapy
Exclusion criteria
* Age \<18 years old * Unable to provide consent * Patients with hemoglobin less than 10 g/dL (to minimize the impact of potential iatrogenic anemia)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary end point is the number and type of mutations detectable in the circulating tumor DNA blood samples. | 1 year |
Countries
United States
Outcome results
None listed